Mediar Therapeutics is planning to launch a Phase 2 clinical trial to test its experimental therapy MTX-463 in people with idiopathic pulmonary fibrosis (IPF). The company has entered into a global licensing agreement with Eli Lilly to advance the development of MTX-463. Mediar will be responsible for…
How big is the internet? I could just say that it’s big, but I want to provide some facts to shed additional light on the topic. According to Health IT, the internet is anticipated to reach 175 zettabytes in size in 2025. In my world, I deal in gigabytes on…
Broadway performers will sing show tunes at the 15th annual Pulmonary Fibrosis Foundation Broadway Belts for PFF! event, which will be held at New York’s Sony Hall March 10 to raise funds and awareness for pulmonary fibrosis, a disease in which scar tissue forms in the lungs. Tony…
Rapidly spreading wildfires have taken over the news headlines from the Los Angeles area, as I write this column. Dry weather and the Santa Ana winds joined forces to create an inferno there. Wildfires are just one emergency that the pulmonary fibrosis (PF) community must be prepared to…
Inhibiting the HIF2 protein — fully, hypoxia-inducible factor 2 — was found to ease scarring in a mouse model of lung injury and could be a promising therapeutic strategy for treating idiopathic pulmonary fibrosis (IPF), according to the results of new preclinical research. In the lab, a team of…
Each new year brings an influx of marketing about resolutions, hopes, and wishes. If you’re like me, your social media feed is flooded with related ad campaigns this month. A new year often sparks hope for positive changes regarding a person’s physical health, mental wellness, or finances. I don’t typically…
Do you make resolutions for the new year? A revealing joke on the subject has been around for years. In it, an entrepreneur opens and stocks a gym on New Year’s Day to support those who’ve made resolutions to exercise. After the first two weeks, though, the gym equipment is…
Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study identifying the enzyme as a potential therapeutic target for the condition. Experiments showed that FASN was elevated in lung scar…
The investigational therapy LYT-100 (deupirfenidone) significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), outperforming the standard of care therapy Esbriet. PureTech Health’s treatment candidate also caused fewer gastrointestinal side effects in patients. That’s according to top-line data from the ongoing Phase…
The holidays have arrived, which reminds of those passenger-side mirrors that read, “Objects in mirror are closer than they appear.” It wasn’t too long ago that the holidays seemed far away, yet here they are. After I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2017, my health…
Get regular updates to your inbox.
